Schroder Investment Management Group Sells 26,731 Shares of Repligen Co. (RGEN)

Share on StockTwits

Schroder Investment Management Group lessened its position in shares of Repligen Co. (NASDAQ:RGEN) by 5.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 483,227 shares of the biotechnology company’s stock after selling 26,731 shares during the quarter. Schroder Investment Management Group owned approximately 1.10% of Repligen worth $22,615,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Repligen during the 2nd quarter worth approximately $135,000. Smith Asset Management Group LP grew its holdings in shares of Repligen by 1,511.8% during the 2nd quarter. Smith Asset Management Group LP now owns 4,658 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 4,369 shares in the last quarter. Benin Management CORP bought a new position in shares of Repligen during the 2nd quarter worth approximately $235,000. GSA Capital Partners LLP bought a new position in shares of Repligen during the 2nd quarter worth approximately $250,000. Finally, Bayesian Capital Management LP bought a new position in shares of Repligen during the 1st quarter worth approximately $228,000. 92.50% of the stock is currently owned by institutional investors.

Repligen stock opened at $54.01 on Friday. The company has a market cap of $2.43 billion, a P/E ratio of 78.58, a P/E/G ratio of 4.46 and a beta of 0.69. Repligen Co. has a one year low of $29.56 and a one year high of $58.99.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported $0.16 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.02). The company had revenue of $47.73 million for the quarter, compared to the consensus estimate of $45.84 million. Repligen had a return on equity of 5.05% and a net margin of 13.49%. Repligen’s quarterly revenue was up 47.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.20 EPS. On average, analysts forecast that Repligen Co. will post 0.71 earnings per share for the current fiscal year.

In other Repligen news, major shareholder Roy T. Eddleman sold 33,142 shares of Repligen stock in a transaction on Monday, August 6th. The stock was sold at an average price of $49.05, for a total value of $1,625,615.10. Following the completion of the transaction, the insider now owns 413,985 shares in the company, valued at approximately $20,305,964.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Anthony Hunt sold 27,566 shares of Repligen stock in a transaction on Monday, September 10th. The shares were sold at an average price of $57.71, for a total value of $1,590,833.86. Following the completion of the transaction, the chief executive officer now owns 255,017 shares of the company’s stock, valued at approximately $14,717,031.07. The disclosure for this sale can be found here. In the last quarter, insiders sold 88,884 shares of company stock valued at $4,693,683. Corporate insiders own 1.40% of the company’s stock.

Several equities analysts recently commented on the company. Stephens raised their target price on Repligen from $50.00 to $55.00 and gave the stock an “average” rating in a research report on Tuesday, July 10th. Janney Montgomery Scott restated a “buy” rating on shares of Repligen in a research report on Thursday, October 4th. BidaskClub upgraded Repligen from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 24th. Zacks Investment Research downgraded Repligen from a “hold” rating to a “sell” rating in a research report on Tuesday, August 7th. Finally, Citigroup raised their target price on Repligen from $45.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, July 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $51.86.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: What are the components of an earnings report?

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply